Teva Pharmaceutical Industries Ltd.

Company profile

• Global biopharmaceutical company built on a large generics platform.
• Incorporated in Israel on February 13, 1944; successor to several earlier Israeli corporations dating back to 1901.
• Headquarters: Israel; operations worldwide with a significant presence in the United States, Europe and other markets.
• Workforce and footprint: approximately 34,000 employees across 57 markets; 33,950 employees as of December 31, 2025.
• Core strategy: Pivot to Growth — grow innovative medicines and biosimilars, expand high-value generics, and transform the organization for efficiency and modernization.

Segments and geographic footprint

Three operating segments:

• United States Segment: leading U.S. generics company; markets innovative CNS, respiratory, oncology and other medicines; includes the Anda distribution business.
• Europe Segment: major European generics, OTC and biosimilars presence; includes CNS and respiratory innovative medicines.
• International Markets Segment: operates outside the U.S. and Europe, integrating branded generics, OTC, biosimilars and innovative medicines across more than 35 countries.

Corporate actions:

• On March 31, 2025, the Teva-Takeda Japan venture was deconsolidated following its sale.
• The company continues to divest or optimize assets as part of the Pivot to Growth program.

Product portfolio and business offerings

• Generics (including biosimilars and OTC): broad portfolio with top-three market positions in several countries; emphasis on high-value, complex generics to offset pricing pressures.
• Biosimilars: growing pipeline and multiple product launches (examples include TRUXIMA, HERZUMA, RANIVISIO, SIMLANDI, SELARSDI, EPYSQLI, FYMSKINA); ongoing collaborations to expand U.S. and EU access.
• Innovative medicines: focus areas include CNS, neuropsychiatry, movement disorders, migraine, multiple sclerosis, oncology and respiratory; patient support programs and payer engagement support access and adherence.
• CNS highlights: AUSTEDO (deutetrabenazine) and AUSTEDO XR for tardive dyskinesia and Huntington’s-related chorea; AJOVY (fremanezumab) for migraine prevention; UZEDY (risperidone) LAI for schizophrenia and bipolar disorder; COPAXONE (glatiramer acetate) for multiple sclerosis.
• Oncology and respiratory: BENDEKA (bendamustine) and TREANDA in the U.S.; inhalation portfolio including ProAir, QVAR, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, AirDuo RespiClick and MDPI devices.
• Other activities: API sales, contract manufacturing services, and Medis out-licensing via Teva’s platform.

Pipeline and collaborations:

• Late-stage candidates in neuroscience and immunology, including anti-TL1A programs and long-acting formulations (examples: olanzapine LAI, emrusolmin, duvakitug).
• Biosimilar targets include denosumab (Prolia/Xgeva), Simponi/Simponi Aria, and Eylea; collaborations with Alvotech and others for U.S./EU markets.
• Select collaborations:
  • Samsung Bioepis: EPYSQLI (eculizumab) in the U.S. (Teva commercialization; supply/development by Samsung Bioepis) with a U.S. launch in 2025.
  • Formycon: FYB203 (aflibercept) in Europe (AHZANTIVE), with Teva leading commercialization in designated regions.
  • Prestige Biopharma: Tuznue (trastuzumab) across most of Europe.
• Regulatory approvals: EMA approvals for PONLIMSI (denosumab) and DEGEVMA (denosumab) in 2025.

Scale, operations and manufacturing

• Finished dosage and packaging: 33 plants in 21 countries.
• 2025 production: ~66 billion tablets/capsules and ~600 million sterile units.
• Supply strategy: mix of Teva-owned facilities and external contract manufacturers, with multi-source supply to mitigate risk; ongoing plant optimization and divestitures to improve cost efficiency and modernize operations.

Research and development (R&D)

• R&D focus: innovative medicines, generics (including high-value and complex generics), and biosimilars.
• Generic R&D: supports a broad global pipeline (more than 900 generic products in the pre-approved pipeline) across solid oral, inhalation, semi-solid, sterile formulations and delivery systems.
• Innovative/biosimilar R&D: confirmatory trials and regulatory strategy supported by strategic partners to accelerate development and commercialization.
• Global R&D and API capabilities: centralized innovation engine spanning small molecules, biologics and high-potency APIs; API R&D covers process development, fermentation and specialized technologies.

Growth initiatives and AI

Pivot to Growth four-pillar strategy:

• Accelerate growth of key innovative products and biosimilars (examples: AUSTEDO, AJOVY, UZEDY).
• Advance the late-stage innovative pipeline and expand the biosimilars footprint.
• Sustain the generics business with a focus on high-value, complex products and an extensive pipeline.
• Transform operations to improve efficiency, with an announced net savings target of about $700 million through 2027 (targeted savings for 2025 achieved).

AI initiatives:

• Selective deployment of AI and machine learning to optimize clinical trial planning and management, R&D, manufacturing, supply chain, financial forecasting and customer engagement, with an emphasis on responsible and ethical use.

Financial snapshot highlights

• 2025 generic medicines revenues: $9,421 million (55% of total revenues).
• Implied total revenues for 2025: approximately $17.1 billion.
• Consolidated debt: about $16,807 million as of December 31, 2025.
• Divestitures and transactions: deconsolidation of the Teva-Takeda Japan venture (effective March 31, 2025); ongoing API divestiture process with a renewed sales process announced November 5, 2025.
• Employees: 33,950 globally as of December 31, 2025 (reported full-time-equivalent range 33,346–35,686 across 2023–2025).

Regulatory and compliance environment

• Operates under extensive global regulatory frameworks (FDA, EMA, MHRA and others) and within complex pricing and reimbursement systems.
• Ongoing litigation, antitrust and patent matters, and government investigations related to pricing, marketing and manufacturing practices.
• Compliance with data protection and cybersecurity rules (HIPAA, GDPR and other privacy laws) and evolving AI and technology regulations.
• Environmental, health and safety (EHS) and sustainability requirements are managed through ongoing initiatives under Teva’s Healthy Future program.

Where to find more

• Note 19: major customers.
• Notes 2 and 22: divestitures and business combinations.
• Item 7, MD&A: segment-level revenue and performance details.

In summary, Teva is a global biopharmaceutical company anchored by a large generics business, with a growing biosimilars and innovative medicines portfolio, substantial manufacturing capacity, and an active strategy to accelerate growth while modernizing operations. In 2025 the company reported $9.421 billion in generic medicines revenues (55% of total revenues), employed about 33,950 people at year-end, and produced roughly 66 billion tablets/capsules and 600 million sterile units.